What the latest earnings mean for Baxter International (BAX)

Baxter International (BAX) is back in focus after its fourth quarter 2025 update combined higher sales with weaker profitability, cautious 2026 guidance, and a sharp market reaction to the softer earnings outlook.

The earnings-driven sell off has come on top of a longer slump, with the share price at US$19.79 after a 1 day share price return of 5.77% but a 1 year total shareholder return of 34.63% decline and a 5 year total shareholder return of 71.93% decline. This suggests that short term trading interest contrasts with a more cautious long term record as Baxter works through margin pressure, goodwill impairments and a muted 2026 outlook.

If Baxter’s update has you reassessing healthcare exposure, this could be a useful moment to look across the sector using our screener of 25 healthcare AI stocks as potential comparison points.

With sales holding up, profits under strain, years of negative shareholder returns and the share price sitting below some intrinsic value and analyst estimates, is Baxter now trading at a discount, or is the market already pricing in its future growth?

Most Popular Narrative: 14.5% Undervalued

At $19.79, Baxter International sits below the most followed fair value estimate of $23.13, which is built on detailed forecasts for revenue, margins and earnings power.

Normalization of hospital purchasing patterns and patient admissions is expected to drive increased utilization of Baxter's core IV solutions and infusion systems as fluid conservation efforts abate, providing upside to revenue growth and margin expansion as volumes recover.

Read the complete narrative. Read the complete narrative.

Curious what kind of revenue run rate and margin profile have to line up for that valuation to make sense? The narrative uses a specific mix of gradual top line growth, a return to positive net income and a re rated earnings multiple. If you want to see exactly how those moving parts are combined, the full story lays out the numbers step by step.

Result: Fair Value of $23.13 (UNDERVALUED)

However, the narrative still hinges on hospital IV usage normalizing and Novum IQ quality concerns easing, and setbacks on either front could quickly challenge that 14.5% discount.

Build Your Own Baxter International Narrative

If you see the assumptions differently or prefer to work directly with the numbers yourself, you can frame your own Baxter view in just a few minutes, starting with Do it your way.

A great starting point for your Baxter International research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.

Looking for more investment ideas?

If you stop with just one stock on your radar, you could miss opportunities that fit you better, so give yourself options and see what else stands out.

• Prioritize quality by scanning for companies with stronger balance sheets and fundamentals using our solid balance sheet and fundamentals stocks screener (45 results) to see which names hold up under closer scrutiny.
• Spot potential value by checking our 53 high quality undervalued stocks, where pricing and fundamentals come together to highlight candidates that may warrant a deeper look.
• Secure steady income by reviewing our 12 dividend fortresses and see which higher yielding companies line up with the kind of cash returns you want from your portfolio.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.